Related Experiment Video
Updated: Feb 25, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here
Michael S May1,2,3, Wungki Park1,2,3, Eileen M O'Reilly4,5,6
1David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies and is a rising cause of morbidity and mortality. An immunosuppressive, hostile tumor microenvironment, and KRAS-driven biology have contributed to poor outcomes in PDAC. Recent breakthroughs in targeting tumors with homologous repair deficiency, KRASG12C mutations, rare gene fusions, and other molecular abnormalities have improved outcomes in subsets of patients. KRAS inhibitors, both allele specific and pan(K)RAS, claudin-targeting biologics, and PRMT5 inhibitors have demonstrated single agent activity in pretreated, biomarker selected PDAC. An improved understanding of the tumor immune microenvironment has facilitated the development of promising cancer vaccines and immunomodulating agents. This review summarizes the current state of PDAC therapeutics and describes drug development targets that will transform outcomes in PDAC in the proximate future.
Insights
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer due to its tumor microenvironment and KRAS mutations. Novel therapies targeting molecular abnormalities and the immune system offer improved outcomes for PDAC patients.
Area of Science:
- Oncology
- Cancer Biology
- Translational Medicine
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with poor patient outcomes.
- The tumor microenvironment and KRAS-driven mutations contribute to PDAC's aggressive nature and treatment resistance.
Purpose of the Study:
- To review current therapeutic strategies for PDAC.
- To highlight emerging drug development targets for improving PDAC patient outcomes.
Main Methods:
- Review of recent scientific literature on PDAC therapeutics.
- Analysis of targeted therapies and immunomodulating agents.
Main Results:
- Targeting homologous repair deficiency, KRAS mutations (e.g., KRAS G12C), and other molecular alterations shows promise.
- KRAS inhibitors, claudin-targeting biologics, and PRMT5 inhibitors exhibit single-agent activity in pretreated PDAC.
- Advances in understanding the tumor immune microenvironment are driving development of cancer vaccines and immunomodulators.
Conclusions:
- Recent therapeutic breakthroughs offer new hope for PDAC patients.
- Future research should focus on novel drug targets to further improve survival rates in PDAC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment: